Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 274
- Registration Number
- NCT01713530
- Locations
- 🇳🇴
Novo Nordisk Investigational Site, Stavanger, Norway
Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT01710696
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Zaragoza, Spain
Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2287
- Registration Number
- NCT01709929
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- Drug: biphasic human insulin 30
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01707160
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Leeds, United Kingdom
Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 753
- Registration Number
- NCT01707134
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, York, United Kingdom
A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
Phase 1
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone Deficiency
- Interventions
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 35
- Registration Number
- NCT01706783
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Stockholm, Sweden
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
Phase 2
Terminated
- Conditions
- Ulcerative ColitisInflammation
- Interventions
- Drug: placebo
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT01706159
Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women
Phase 4
Completed
- Conditions
- HealthyMenopause
- Interventions
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 191
- Registration Number
- NCT01705249
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Uddevalla, Sweden
A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT01704417
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 89
- Registration Number
- NCT01704378
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath